Exopharm Ltd (ASX: EX1) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Exopharm Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $4.83 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 439.42 million
Earnings per share -0.036
Dividend per share N/A
Year To Date Return -79.28%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Exopharm Ltd (ASX: EX1)
    Latest News

    ASX bank profit upgrade Red rocket and arrow boosting up a share price chart
    Healthcare Shares

    Why did the Exopharm (ASX:EX1) share price surge 12% today?

    The Exopharm share price is rising today after the company announced positive clinical trial results in humans.

    Read more »

    falling healthcare asx share represented by doctor with head in hands
    Healthcare Shares

    Exopharm (ASX:EX1) share price plunges 17% after animal testing results

    The Exopharm (ASX:EX1) share price is sliding today after the company's osteoarthritis animal treatments showed no effect on the rats…

    Read more »

    EX1 ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Exopharm Ltd

    Exopharm Ltd is a biopharmaceutical company that engages in the development of regenerative medicine in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. The company operates in one segmentnamely the research and development of biopharmaceutical drugs. Revenue is generated from Australia.

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    28 Apr 2023 Jason Watson Issued 380,000 $3,800
    Rights issue.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Ian Edward Dixon Chief Executive OfficerManaging Director May 2013
    Dr Dixon is a co-inventor of the patented LEAP Technology owned by Exopharm and is also a co-inventor of other Exopharm technologies. Dr Dixon brings to the Board a technical and entrepreneurial background in founding, building and running technology-based companies, in recognising the potential commercial value of early-stage drug development, and in understanding the challenges involved in drug development
    Mr Mark Davies Non-Executive ChairmanNon-Executive Director Jun 2023
    Mr Davies has over 25 years of experience in trading, investment banking and providing corporate advice. He worked at Montagu Stockbrokers before co-founding investment banking firm Cygnet Capital and more recently 1861 Capital. Mark specialises in providing corporate advice and capital raising services to emerging companies seeking business development opportunities and funding from the Australian market
    Mr Clarke Barlow Non-Executive Director Feb 2023
    Mr Barlow is a Financial Adviser with 22 years of experience in the Financial Services Industry in Australia and the United Kingdom (UK). Mr Barlow has experience in structuring, operations and risk management of institutional exotic derivatives in the UK and has been responsible for establishing and managing derivatives trading desks for Australian based investment banks. Since 2007 Mr Barlow has serviced retail and institutional clients advising on share portfolios, derivatives, and identification of early-stage opportunities across a variety of industries and sectors. He also provides corporate advisory services for ASX listed companies across a variety of industries, with a focus on growth opportunities, providing them with advice on business models & strategy, structuring of pre-IPO and IPO fund raisings, reverse takeovers, capital raisings, M&A, investor relations and capital markets advice. Mr Barlow is a Founder and Director of AMG Acquisition Corp, a publicly listed company on the Toronto Venture Exchange (TSXV).
    Mr David James Franks Company Secretary Sep 2021
    Dr Michael West Chief Technology Officer
    David James Franks Company Secretary
    Mr David Oxley President - International

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Altnia Holdings Pty Ltd (Dixon Family A/C) 28,258,627 6.43%
    Kyriaco Barber Pty Ltd 19,287,557 4.39%
    Zessham Pty Ltd (Zessham A/C) 13,200,000 3.00%
    Dixson Trust Pty Limited 11,712,000 2.67%
    Citicorp Nominees Pty Limited 8,987,356 2.05%
    Canary Capital Pty Ltd 8,158,333 1.86%
    Harlund Investments Pty Ltd (Hart Family Super Fund A/C) 7,500,000 1.71%
    Mr Michael Francis Mcmahon & Mrs Susan Lesley Mcmahon (Mcmahon Super Fund A/C) 7,500,000 1.71%
    Wfc Nominees Australia Pty Ltd 7,500,000 1.71%
    Superhero Secuities Limited (Client A/C) 6,260,095 1.42%
    Mr Paul James Madden 5,750,000 1.31%
    Wolseley Road #1 Pty Ltd (Adsaleum Family A/C) 4,800,000 1.09%
    Huon Pine Pty Ltd (Huon Pine Investment A/C) 4,752,831 1.08%
    Mr Paul Joseph Cozzi 4,000,000 0.91%
    Oldview Enterprises Pty Ltd (The Priestley A/C) 4,000,000 0.91%
    Mr Prinsloo Marcellus Ziga Dube 3,780,000 0.86%
    Celtic Finance Corp Pty Ltd 3,750,000 0.85%
    Mr Andrew Fay & Mrs Narelle Fay (Andrew Fay Super Fund A/C) 3,750,000 0.85%
    Mr Carlo Bellini 3,750,000 0.85%
    Mrs Ann Hatch 3,525,000 0.80%